Low dose mepolizumab as steroid sparing strategy in HES remission phase

Matteo Maule,Gianenrico Senna,Veronica Batani, Federica Maiolini,Simonetta Friso,Marco Caminati

Journal of Allergy and Clinical Immunology（2023）

引用 0|浏览8

暂无评分

摘要

Hypereosinophilic syndrome (HES) treatment relies mainly on steroids and cytotoxic therapies. Mepolizumab has shown to be effective in reducing disease flares and FDA has approved its use at the dose of 300 mg every 4 weeks as add on therapy in HES patients.

查看译文

关键词

low dose mepolizumab,steroid,remission

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要